Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GHRS 
GH Research PLC (GHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: GHRS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.09
1 Year Target Price $31.09
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 54.51% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 803.90M USD | Price to earnings Ratio - | 1Y Target Price 31.09 |
Price to earnings Ratio - | 1Y Target Price 31.09 | ||
Volume (30-day avg) 8 | Beta 0.98 | 52 Weeks Range 6.72 - 20.50 | Updated Date 10/14/2025 |
52 Weeks Range 6.72 - 20.50 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.73% | Return on Equity (TTM) -16.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 536584129 | Price to Sales(TTM) - |
Enterprise Value 536584129 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.97 | Shares Outstanding 62029395 | Shares Floating 20467219 |
Shares Outstanding 62029395 | Shares Floating 20467219 | ||
Percent Insiders 31.46 | Percent Institutions 70.41 |
Upturn AI SWOT
GH Research PLC
Company Overview
History and Background
GH Research PLC is a biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of mental health disorders. Founded in 2019, the company went public in 2021. They are pioneering the use of 5-MeO-DMT therapies.
Core Business Areas
- Drug Development: Focused on researching and developing novel psychedelic therapies, primarily using 5-MeO-DMT, to treat psychiatric and neurological disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their 5-MeO-DMT formulations.
Leadership and Structure
The company is led by a management team with experience in drug development and psychiatry. The organizational structure reflects a focus on research and clinical trials.
Top Products and Market Share
Key Offerings
- GH001 (5-MeO-DMT nasal spray): An intranasal formulation of 5-MeO-DMT being developed for Treatment-Resistant Depression (TRD). It is in clinical trials. Currently, there is no market share, as it is not yet approved. Competitors include companies developing psilocybin-based therapies such as COMPASS Pathways (CMPS) and ATAI Life Sciences (ATAI).
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging with increasing interest in using psychedelic compounds for treating mental health disorders. There is significant regulatory and social acceptance to still be achieved to enable commercial use.
Positioning
GH Research is positioned as a leader in developing 5-MeO-DMT therapies, differentiating itself from companies focusing on psilocybin or LSD.
Total Addressable Market (TAM)
The TAM for mental health treatments is substantial, estimated to be in the tens of billions of dollars annually. GH Research is aiming to capture a portion of this market with its novel therapies.
Upturn SWOT Analysis
Strengths
- Pioneering work in 5-MeO-DMT therapies
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- High regulatory hurdles
- Reliance on a single compound (5-MeO-DMT)
- Limited clinical data compared to psilocybin
Opportunities
- Potential for breakthrough therapies for treatment-resistant depression
- Expansion into other mental health disorders
- Partnerships with established pharmaceutical companies
Threats
- Regulatory setbacks
- Competition from other psychedelic medicine companies
- Negative public perception of psychedelic drugs
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
- MNMD
Competitive Landscape
GH Research's focus on 5-MeO-DMT sets it apart. They are competing with other companies developing psychedelic therapies, particularly those focused on psilocybin.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and expansion of the company's research programs.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its 5-MeO-DMT therapies. Analyst projections are speculative but generally positive given the potential market.
Recent Initiatives: Recent initiatives include advancing GH001 through clinical trials and expanding research into other 5-MeO-DMT formulations.
Summary
GH Research is a high-risk, high-reward biopharmaceutical company pioneering 5-MeO-DMT therapies for mental health disorders. Its strengths lie in its IP and focus but faces regulatory hurdles and competition. Successful clinical trials are crucial for its growth and shareholder value. Investors should be aware of the speculative nature of the industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- SEC Filings
- Third-Party Analyst Reports (where available)
- Market Data Aggregators
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GH Research PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.ghres.com |
Full time employees 50 | Website https://www.ghres.com | ||
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.